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Background: With greater number of implants being placed in clinical practice, incidence of peri-implant diseases 
are on the rise. It is not known whether chlorhexidine (CHX) improves outcomes in the management of peri-im-
plant diseases. The aim of this systematic review and meta-analysis was to evaluate the role of CHX in improving 
outcomes with non-surgical management of peri-implant mucositis and peri-implantitis.
Material and Methods: An electronic search of PubMed, Scopus, Embase, and CENTRAL (Cochrane Central 
Register of Controlled Trials) databases up to 1st August 2019 was carried out to search for studies evaluating the 
efficacy of CHX for non-surgical management of peri-implant diseases.
Results: Seven studies were included. Four studies evaluated the role of CHX in peri-implant mucositis and three 
in peri-implantitis. Oral prophylaxis with mechanical cleansing of implant surface prior to CHX use was carried 
out in all seven studies. Meta-analysis indicated that use of CHX did not improve probing depths in peri-implant 
mucositis (SMD= 0.11; 95% CI: -0.16 to 0.38; p=0.42, I2= 0%). Similarly, CHX did not significantly reduce prob-
ing depths in patients with peri-implantitis (MD= 1.57; 95% CI: -0.88 to 4.0; p=0.21, I2= 98%). Results on the 
efficacy of CHX in reducing BOP in peri-implantitis are conflicting.
Conclusions: Results of our study indicate that adjunctive therapy with CHX may not improve outcomes with non-
surgical management of peri-implant mucositis. Conclusions with regards to its role in non-surgical management 
of peri-implantitis cannot be drawn. There is a need for more homogenous RCTs with large sample size to define 
the role of CHX in non-surgical management of peri-implant mucositis and peri-implantitis.
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Introduction
Peri-implant mucositis and peri-implantitis are com-
mon pathological conditions affecting implants in 
function. The prevalence of peri-implant mucositis and 
peri-implantitis is estimated to be 19%-65% and 1%-
47% respectively (1). While, peri-implant mucositis is 
a reversible inflammatory lesion that is confined to the 
surrounding implant mucosa, it may progress to peri-
implantitis if left untreated (2). Peri-implantitis is usual-
ly diagnosed on the basis of progressive marginal bone 
loss, probing depths of ≥6mm and presence of bleeding 
on probing (BOP) (3).
The main causative factor for these conditions is be-
lieved to be pathogenous bacteria. However, the clinical 
course may vary depending upon a number of factors 
like previous history of periodontitis, smoking, system-
ic diseases, prosthetic errors etc (4).  Due to structural 
similarity of peri-implant soft tissues and gingiva, a 
homogenous response to biofilm formation in the form 
of inflammatory cell infiltration is seen in both tissues. 
Studies have also established an identical cause-and-
effect relationship after 3-weeks of plaque accumula-
tion around teeth (gingivitis) and implants (peri-implant 
mucositis) (5). Additionally, the anaerobic gram nega-
tive bacterial flora of peri-implantitis has been found to 
be similar to that of periodontitis (6).  In view of the 
homogeneity, treatment protocols used to treat gingi-
vitis and periodontitis have been used for management 
of peri-implant mucositis and peri-implantitis respec-
tively. While the primary line of treatment is disruption 
of biofilm and reduction of bacterial loads, additional 
surgical procedures and adjunctive therapies like use of 
chlorhexidine (CHX), triclosan based dentifrice, abra-
sive air blasting with sodium carbonate, photodynamic 
therapy and use of systemic antibiotics may be utilized 
depending upon the clinical condition (7,8).
CHX is a commonly used topical agent for control and 
prevention of biofilm formation owing to its high sub-
stantivity, bactericidal activity and broad spectrum of 
action (9). However, owing to the implants’ macrostruc-
ture and surface characteristics, the biofilm content on 
an implant surface can be quite different from that of 
natural tooth surface (10,11). The implant surface has 
been shown to favor the presence of pathological bacte-
ria even in the absence of peri-implant disease (10). In 
view of such differences, it is important to know if CHX 
has a role in managing peri-implant diseases. To date, a 
number of studies have evaluated the role of CHX in 
non-surgical treatment of peri-implant mucositis and 
peri-implantitis but with conflicting results (2,12,13). 
In the absence of clear clinical guidelines, the aim of 
this study was to systematically analyze literature and 
carry out a meta-analysis evaluating the role of CHX in 
improving outcomes with non-surgical management of 
peri-implant mucositis and peri-implantitis.
Material and Methods
- Inclusion criteria and Search strategy
This systematic review and meta-analysis is based on the 
guidelines of the PRISMA statement (Preferred Report-
ing Items for Systematic Reviews and Meta-analyses) 
(14) and Cochrane Handbook for Systematic Reviews of 
Intervention (15). The research question to be answered 
was: Does local application of CHX improve outcomes in 
patients undergoing non-surgic¬al treatment of peri-im-
plant mucositis or peri-implantitis? The review protocol 
was prepared prior to initiation of the study.
An open-ended electronic search of articles published 
in the PubMed, Scopus, Embase, and CENTRAL (Co-
chrane Central Register of Controlled Trials) databases 
up to 1st August 2019 was carried out. Search words used 
in various combinations were: “chlorhexidine”, “peri-
implantitis”, “peri-implant mucositis”, “dental implant”, 
“anti-microbial”, “anti-infective”, and “non-surgical”. 
The search strategy with results of PubMed database are 
presented in supplemental content 1.  A hand search of 
references of included studies and relevant review ar-
ticles was also carried out for identification of any ad-
ditional studies.
PICOS (Population, Intervention, Comparison, Outcome, 
and Study design) outline was followed for identifica-
tion of relevant articles. We included randomised con-
trolled trials (RCTs) or controlled clinical trials (CCTs) 
conducted on adult patients (>18years) with peri-implant 
mucositis or peri-implantitis (Population); evaluating any 
form of local application of CHX (Intervention); compar-
ing it with controls (Comparison) and assessing probing 
depth, BOP and/or clinical attachment levels (CAL) (Out-
comes). We excluded in-vitro studies, studies on zirconia 
implants, animal studies, retrospective studies, single 
arm trials, case-series and non-English language studies. 
Studies comparing CHX with other active interventions 
(for e.g. laser therapy, air abrasive therapy), not studying 
any of the inflammatory outcomes (probing depths, BOP, 
CAL) and those evaluating the role of CHX with surgical 
treatment of peri-implant mucositis and peri-implantitis 
were also excluded.
- Data extraction and Outcomes
Literature search was performed by two independent re-
viewers. Title and abstracts of the retrieved studies were 
scrutinized, followed by full-texts evaluation of selected 
articles, for inclusion in the review. Disagreements were 
resolved by discussion to reach a definitive decision. Data 
was extracted by two independent reviewers using an 
abstraction form. The following details were collected: 
Authors, publication year, study type, sample size, selec-
tion criteria, treatment protocol, follow-up period and 
outcomes.
- Risk of bias
Cochrane Collaboration risk assessment tool for RCTs 
was used for quality assessment of the included trials 
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(16). Studies were rated as low risk, high risk, or unclear 
risk of bias for: random sequence generation, allocation 
concealment, blinding of participants and personnel, 
blinding of outcome assessment, incomplete outcome 
data, selective reporting, and other biases.
- Statistical analysis
Review Manager (RevMan, version 5.3; Nordic Co-
chrane Centre [Cochrane Collaboration], Copenhagen, 
Denmark; 2014) was used for the meta-analysis. Meta-
analysis was conducted only if at least 3 studies report-
ed outcomes on the same scale. Anticipating hetero-
geneity amongst studies, a random-effects model was 
used to calculate the pooled effect size. Standardized 
Mean Difference (SMD) and Mean Difference (MD) 
with 95% confidence interval (CI) were used for pool-
ing of continuous variables. Heterogeneity was calcu-
lated using I2 statistic.  I2 values of 25-50% represented 
low, values of 50-75% medium and >75% represented 
substantial heterogeneity.
Meta-analysis of studies on peri-implant mucositis and 
peri-implantitis were carried out separately. Change of 
baseline scores were used for meta-analysis of studies 
on peri-implantitis. In studies where change scores were 
missing, the following equation was used for calculating 
the change in mean and standard deviation (SD) scores: 
Mean (Change)= Mean (After) - Mean (Before) and SD 
(Change)= square root {[SD2(after)- SD2(before)]/2}. A 
sensitivity analysis was carried out to assess influence 
of each study on the pooled effect size. Every study was 
eliminated sequentially to analyze any change in the re-
sults of the meta-analysis. Outcomes not pooled for a 
meta-analysis were presented in descriptive form.
Results
Search results are presented in Fig. 1.  Of the 17 stud-
ies selected for full-text evaluation,  ten studies were 
excluded (17-26). Reasons for exclusion are presented 
in Table 1. A total of seven studies were included in the 
systematic review and meta-analysis (2,12,13,27-30).
Baseline characteristics of included studies is presented 
in Table 2. Six were RCTs (2,13,27-30) while one was a 
CCT (12). Four studies (2,27-29) evaluated the role of 
CHX in peri-implant mucositis while three (12,13,30) 
assessed the drug in patients with peri-implantitis. All 
studies involved titanium implants. Patients were treat-
ed with various forms of CHX which included chips, 
gels, mouth rinses and irrigation devices. Oral prophy-
laxis with mechanical cleansing of implant surface prior 
to drug use was carried out in both groups and in all 
seven studies (2,12,13,27-30). However, CHX treatment 
protocol differed widely. The follow-up of included 
studies ranged from 1 month to 36 months.
Table 1: Reasons for exclusion of studies.
Study Reason for exclusion
Lavigne et al. (15) Experimental sites without BOP at baseline
Renvert et al. (16) Comparison with active treatment (Minocycline)
John et al. (17) Study on zirconia implants
John et al. (18) Comparison with active treatment (air abrasive device)
Schwarz et al. (19) Comparison with active treatment (laser)
Schwarz et al. (20) Study on zirconia implants
Sahm et al. (21) Comparison with active treatment (air abrasive device)
Lombardo et al. (22) Comparison with active treatment (topical desiccant)
Carral et al. (23) Animal study
Kadkhoda et al. (24) Did not study effect of CHX on BOP, PD and CAL
BOP, Bleeding on probing; PD, Probing Depth; CAL, Clinical attachment level; CHX, Chlorhexidine
Fig. 1: Study flow-chart.
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16 12 Mechanical cleansing with rubber 
cups and polishing paste with local 
irrigation of CHX, topical applica-
tion of CHX gel and 0.12% CHX 
mouthwash BD for 10 days. Control 
group received same treatment with-
out CHX
Reduction of plaque and 
inflammation, improve-
ment in PD, gain in CAL 
seen with both study and 
control groups. Addition 










14 15 Mechanical debridement with tita-
nium coated Gracey and  carbon fiber 
curettes followed by brushing around 
the implant using CHX gel BD for 4 
weeks. Control group received same 
treatment with placebo gel
Reduction in number of 
BOP sites and PD in both 
groups. Addition of CHX 









22 14 Mechanical debridement with plastic 
scalers and polyetheretherketone-
coated ultrasonic instruments fol-
lowed by topical CHX gel applica-
tion once with CHX disinfection of 
tongue and tonsils. 0.2% CHX mouth 
rinse BD and tonsil spraying OD for 
14 days. Control group received same 
treatment without CHX.
Reduction in PD and 
BOP sites in both groups. 










with PD of 
6-10mm
40 37 Mechanical debridement with ultra-
sonic instruments followed by place-
ment of up to four 2.5mg CHX chips,. 
Patients re-assessed at 2,4,6,8,12,18 
weeks and chips re-inserted when PD 
still >6mm. Control group received 
same treatment with placebo chips
No significant differ-
ence in gain in CAL 
and reduction of PD 
between the two groups 
, reduction in number of 









with PD of 
≥5mm
19 20 Oral prophylaxis  followed by use of 
water jet device containing 5ml CHX 
gel at home BD. Control group re-
ceived same treatment without water 
jet usage
No significant difference 
in reduction of PD and 
sites with BOP between 
study and control groups
3m
Mene-





61 58 Scaling and root planning followed 
by subgingival irrigation with 0.12% 
CHX 3times within 10min and 0.12% 
CHX mouthwash BD 30mins after 
brushing for 14 days. Control group 
received same treatment with placebo
Significant reduction of 
PD, BOP, GBI, PI in both 
groups. Addition of CHX 








with PD of 
≥5mm
40 35 Mechanical debridement of implant 
surface with round bur without re-
moval of granulation tissue followed 
by filling of peri-implant pocket by 
0.2% CHX gel and 3% chlortetracy-
cline hydrochloride gel around im-
plant surface. Control group received 
same treatment, except for gel place-
ment, saline irrigation of pockets 
carried out for 1 min
Greater treatment suc-
cess in study group. 
Significantly greater 





RCT, randomized control trial; CCT, Controlled clinical trial; CHX, chlorhexidine; OD, once daily; BD, twice daily; PD; probing depth; CAL; 
clinical attachment level; m, months; BOP, bleeding on probing; GBI, gingival bleeding index; PI, plaque index; min, minute.
Table 2: Characteristics of included studies.
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Outcomes
- Probing Depth
Pocket probing depth around the implant was evalu-
ated by  all seven studies (2,12,13,27-30). Out of the 
four studies on peri-implant mucositis (2,27-29), three 
studies (27-29) reported mean probing depths around 
the implant while one (2) reported sum of the four prob-
ing sites around the implant. Meta-analysis indicated no 
difference in probing depths between the study and con-
trol groups at 2-3 months of follow-up (SMD= 0.11; 95% 
CI:-0.16 to 0.38; p=0.42, I2= 0%) (Fig. 2). Meta-analysis 
for probing depths in patients with peri-implantitis was 
carried out using change in baseline scores. Our pooled 
analysis failed to demonstrate any significant beneficial 
effect of CHX in improving probing depths in peri-im-
plantitis at 3-6 months of follow-up (MD= 1.57; 95% 
CI:-0.88 to 4.0; p=0.21, I2= 98%) (Fig. 2). There was no 
change in the significance and direction of effect size on 
sensitivity analysis.
- Bleeding on Probing
Effects of CHX on BOP was studied by all seven trials 
(2,12,13,27-30). However, due to heterogeneity in re-
porting of data, meta-analysis could not be carried out. 
Results of individual studies are presented in descrip-
tive form.
Porras et al. (29) in their cohort of peri-implant mucosi-
tis patients found as significant reduction of BOP sites 
in both study and control groups. There was no signifi-
cant inter-group difference. However, data of individual 
groups was not presented in the article. Heitz-Mayfield 
et al. (2) in their study of 29 implants with peri-implant 
mucositis, found significant reduction of mean num-
ber of BOP-positive sites with CHX (from a baseline 
of 2.5±1 to 1.1±0.9 at 3 months) and placebo (from a 
baseline of 2.3±1 to 0.7±0.9 at 3 months). There was no 
statistical significant difference between CHX and pla-
cebo at 1 months and 3 months (p>0.10).
Thone-Muhling et al. (27) reported significant re-
duction of BOP positive sites with CHX (change of 
-0.09±0.09) as compared to control group (change of 
-0.13±0.17) at 2 months (p<0.05). Similar results were 
noted at 4 months but not after 8 months of follow-up. 
Menezes et al. (28) reported percentage of BOP posi-
tive sites (%BOP) around implants with peri-implant 
mucositis. They found statistical significant reduction 
of %BOP sites with CHX (75.82±33.98 to 45.76±34.85) 
and placebo (67.54±34.38 to 41.08±41) at 6 months of 
follow-up, however, there was no significant inter-group 
difference.
Machtei et al. (30) in their RCT on peri-implanti-
tis, reported a significant reduction in %BOP with 
CHX (reduction of 57.5±7.92) and placebo (reduc-
tion of 45.5±8.8) with no significant inter-group 
difference at 6 months. On the other hand, Levin 
et al. (13) in their trial of peri-implantitis patients, 
reported significant beneficial effect of CHX water 
jet in reduction of BOP positive sites as compared to 
placebo at 3 months (p=0.011). Complete data was 
not available in the published article. Crespi et al. 
(12) in their RCT reported that addition of CHX to 
non-surgical therapy results in significantly greater 
reduction of %BOP sites (94.8±10.4 to 16.8±18.2) as 
compared to placebo (92.5±11.8 to 78.5±1.2%) at 3 
months (p<0.001). Similar difference was seen at 
36-months of follow up.
- Clinical attachment levels
Two studies reported the effect of CHX on CAL in peri-
implant mucositis. In the trial of Porras et al. (29), statis-
tical significant change in CAL was seen in both study 
and control groups. The authors concluded that addition 
of CHX did not significantly improve outcomes. Thone-
Muhling et al. (27) reported significant improvement in 
CAL in control group but not in the CHX group after 8 
months of follow-up.
Fig. 2: Forrest plot of probing depth A) for peri-implant mucositis B) for peri-implantitis.
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Two trials reported CAL outcomes in peri-implantitis 
patients. Machtei et al. (30) reported significant in-
crease in CAL with both CHX (2.21±0.23mm) and pla-
cebo (1.56±0.25mm) in patients with peri-implantitis at 
6 months with no statistical significant difference be-
tween the two groups (p=0.05). Crespi et al. (12) re-
ported a significant improvement of CAL from a base-
line of 8.18±1.29mm to 3.67±0.81mm with CHX and 
a similar significant improvement from a baseline of 
7.55±1.18mm to 6.69±1.43mm with placebo at 3months. 
However, outcomes with CHX were significantly bet-
ter than placebo at 3months, 24 months and 36 months 
(p<0.001).
- Risk of bias assessment
Authors judgement of risk of bias in included studies 
is presented in Fig. 3. Adequate method of randomiza-
tion and allocation concealment was reported in four 
(2,27,28,30) and two trials (2,30) respectively. Blinding 
of personnel and participants was adequately reported 
in two studies (2,30) while blinding of outcome assess-
ment was reported by only one trial (30).
Discussion
The primary aim of this study was to evaluate whether 
supplementation of CHX with non-surgical therapy 
resulted in improved outcomes in the management of 
peri-implant mucositis and peri-implantitis. Paucity of 
RCTs and CCTs resulted in inclusion of only four stud-
ies for peri-implant mucositis and three studies for peri-
implantitis in our systematic review.
Peri-implant mucositis in experimental conditions has 
been found to be reversible once oral hygiene measures 
are reinforced and biofilm is mechanically disrupted 
(31). Since peri-implant mucositis acts as a precursor to 
peri-implantitis, early  management of this reversible 
process may reduce the incidence of peri-implantitis 
and implant failures (32). In search for an optimal man-
agement protocol for peri-implant mucositis, a number 
of adjunctive measures to mechanical therapy have been 
studied (7,8). In 2008, Renvert et al. (33) in a literature 
review  concluded that while non-surgical mechanical 
therapy is effective in the management of peri-implant 
mucositis, addition of anti-microbial mouth rinses en-
hanced the outcomes of mechanical therapy for muco-
sitis lesions. However, in 2015, Schwarz et al. (34) in 
a systematic review and meta-analysis concluded that 
adjunctive antiseptic, antibiotic (local and systemic) or 
mechanical therapy did not improve outcomes with me-
chanical therapy of peri-implant mucositis. While these 
previous reviews have been more generalized in their 
definition of “adjunctive therapies”, our study evaluated 
a specific adjunctive therapy: CHX. Our meta-analysis 
revealed that addition of CHX to mechanical therapy 
resulted in no difference in probing depths at short term 
follow up.  Also, none of the four studies reported statis-
tical significant difference in the number of BOP posi-
tive sites between the two groups. Two studies reported 
no difference in CAL with or without CHX. These re-
sults should be interpreted with caution as there was 
wide variation in the method of CHX delivery and total 
treatment time in the included studies.
Studies have shown that periodontopathogens may not 
be restricted to periodontal pockets alone, but they may 
also establish on tongue, tonsils and other oral mucosal 
sites (35). Therefore, Thone-Muhling et al. (27) stud-
ied the “one stage full-mouth disinfection” protocol of 
Quirynen et al. in peri-implant mucositis wherein disin-
fection of tongue and tonsils were also carried out with 
CHX, unlike the other three included studies. Secondly, 
Felo et al. (36) have suggested that CHX administered 
via powered sub-gingival irrigation may result in better 
outcomes than mouth rinses alone. CHX was used in 
gel from by Heitz-Mayfield et al. (2), as a mouth rinse 
by Menezes et al. (28), Thone-Muhling et al. (27) and 
both gel and mouth-rinse by Porras et al. (29). None of 
the included trials in our review studied the effect of 
subgingival CHX irrigation for peri-implant mucositis. Fig. 3: Risk of bias summary. 
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Due to paucity of studies and limited sample size on 
included trials, the exact role of the mode of CHX deliv-
ery and extent of disinfection in influencing outcomes 
in peri-implant mucositis cannot be elicited.
While non-surgical management is considered to be ef-
fective for peri-implant mucositis, the optimal treatment 
protocol for the management of peri-implantitis is still 
debatable. Renvert et al. (33) suggest that non-surgical 
therapy alone is not effective in the management of peri-
implantitis. Fagglon et al. (37) in their meta-analysis of 
eleven studies report that debridement in conjunction 
with antibiotics resulted in greater probing depth re-
duction than debridement alone. The role of CHX as an 
adjunctive therapy to non-surgical management of peri-
implantitis is also unclear. Of the three studies included 
in our review, Crespi et al. (12) reported significantly 
better success rates in the study group (100%) as com-
pared to the control group (31.4%). This is in contrast 
with the studies of Machtei et al. (30) and Levin et al. 
(13) which reported no significant difference in results 
between CHX and control. The variation in outcomes 
may be explained by the different treatment method-
ology employed by Crespi et al. (12). Addition of 3% 
chlortetracycline hydrochloride gel along with CHX 
around the implant surface may have reduced the bac-
terial load and detoxified the implant surface in their 
trial. The authors also hypothesized  that leaving the 
granulation tissue in the soft tissue pocket may have re-
sulted in proliferation of cells with embryonic stem cell 
properties thereby leading to better healing of tissues 
(38). With large variations in methodology amongst the 
three studies, definite conclusions on the role of CHX 
in non-surgical management of peri-implantitis cannot 
be drawn.
The lack of effectiveness of CHX as an adjunctive 
therapy for peri-implant disease as seen in majority of 
included studies may be explained by the difference 
in the drug’s substantivity between tooth and implant 
surfaces. While CHX demonstrates superior bonding to 
tooth surface, its adhesion on titanium depends upon 
the surface roughness and CHX concentration (39). Ryu 
et al. (40) have demonstrated that CHX adsorbed on the 
non-treated implant surface is rapidly released in 3 days 
while preparation of implant surface with sand blasting 
and acid etching may result in better CHX uptake. Due 
to a variety of implants and different drug concentra-
tions used in the seven studies, the actual CHX adsorp-
tion and the duration of the following anti-microbial 
effect may have skewed results. New evidence also sug-
gests that lack of better response after implant decon-
tamination with chemotherapeutic agents may be due to 
alteration of implant surface by the drugs. Kotsakis et 
al. (41) have shown that CHX may alter the biocompat-
ibility of implant surface and therefore should not be 
recommended for detoxification of implant surface. In 
light of this new evidence, further studies in-vitro stud-
ies need to be carried out to evaluate the effects of CHX 
on titanium surfaces.
The drawbacks of our review need to be mentioned. 
Foremost, only seven studies were available for inclu-
sion with many trials of small sample size. Secondly, 
there were only two studies (2,30) with minimal risk of 
bias therefore the overall quality of evidence was not 
high. Thirdly, there was wide variation in the methodol-
ogy of the included studies making comparisons diffi-
cult. Lastly, there were differences in the treatment pro-
tocol with different concentrations and forms of CHX 
tested for different durations. These variations may 
have influenced overall results.
In spite of the limitations, to the best of our knowledge, 
our study is the first systematic review and meta-anal-
ysis evaluating the role of CHX for peri-implant mu-
cositis and peri-implantitis. The results of our study 
indicate that adjunctive therapy with CHX may not im-
prove outcomes with non-surgical management of peri-
implant mucositis. Conclusions with regards to its role 
in non-surgical management of peri-implantitis cannot 
be drawn. The present quality of evidence is weak due 
to limited studies and methodological heterogeneity. 
There is a need for high quality RCTs with homogenous 
methodology to further study the role of CHX as an 
adjunctive therapy for peri-implant mucositis and peri-
implantitis.
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